These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 29483095

  • 1. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma.
    Cheng BY, Lau EY, Leung HW, Leung CO, Ho NP, Gurung S, Cheng LK, Lin CH, Lo RC, Ma S, Ng IO, Lee TK.
    Cancer Res; 2018 May 01; 78(9):2332-2342. PubMed ID: 29483095
    [Abstract] [Full Text] [Related]

  • 2. SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer.
    Kim SY, Shen Q, Son K, Kim HS, Yang HD, Na MJ, Shin E, Yu S, Kang K, You JS, Yu KR, Jeong SM, Lee EK, Ahn YM, Park WS, Nam SW.
    Oncogene; 2021 Jul 01; 40(28):4652-4662. PubMed ID: 34140644
    [Abstract] [Full Text] [Related]

  • 3. Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma.
    Li N, Jiang J, Fu J, Yu T, Wang B, Qin W, Xu A, Wu M, Chen Y, Wang H.
    J Exp Clin Cancer Res; 2016 Sep 13; 35(1):140. PubMed ID: 27619757
    [Abstract] [Full Text] [Related]

  • 4. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
    Zhao X, Zheng F, Li Y, Hao J, Tang Z, Tian C, Yang Q, Zhu T, Diao C, Zhang C, Chen M, Hu S, Guo P, Zhang L, Liao Y, Yu W, Chen M, Zou L, Guo W, Deng W.
    Redox Biol; 2019 Jan 13; 20():427-441. PubMed ID: 30419422
    [Abstract] [Full Text] [Related]

  • 5. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.
    Ching RHH, Sze KMF, Lau EYT, Chiu YT, Lee JMF, Ng IOL, Lee TKW.
    Oncotarget; 2017 Apr 04; 8(14):23507-23516. PubMed ID: 28186991
    [Abstract] [Full Text] [Related]

  • 6. Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells.
    Liu Z, Yan R, Al-Salman A, Shen Y, Bu Y, Ma J, Luo DX, Huang C, Jiang Y, Wilber A, Mo YY, Huang MC, Zhao Y, Cao D.
    Biochem J; 2012 Mar 01; 442(2):273-82. PubMed ID: 22329800
    [Abstract] [Full Text] [Related]

  • 7. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC, Tung SL, Chen YL, Chen PM, Chu PY.
    BMC Cancer; 2018 May 30; 18(1):609. PubMed ID: 29848298
    [Abstract] [Full Text] [Related]

  • 8. Regulation of aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma.
    Liu TA, Jan YJ, Ko BS, Wu YJ, Lu YJ, Liang SM, Liu CC, Chen SC, Wang J, Shyue SK, Liou JY.
    Oncotarget; 2015 Nov 17; 6(36):38967-82. PubMed ID: 26516929
    [Abstract] [Full Text] [Related]

  • 9. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
    Leung HW, Leung CON, Lau EY, Chung KPS, Mok EH, Lei MML, Leung RWH, Tong M, Keng VW, Ma C, Zhao Q, Ng IOL, Ma S, Lee TK.
    Cancer Res; 2021 Jun 15; 81(12):3229-3240. PubMed ID: 33903122
    [Abstract] [Full Text] [Related]

  • 10. NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
    Leung HW, Lau EYT, Leung CON, Lei MML, Mok EHK, Ma VWS, Cho WCS, Ng IOL, Yun JP, Cai SH, Yu HJ, Ma S, Lee TKW.
    Cancer Lett; 2020 Apr 28; 476():48-56. PubMed ID: 32061952
    [Abstract] [Full Text] [Related]

  • 11. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul 28; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 12. High-throughput screening identified pacritinib as a promising therapeutic approach to overcome lenvatinib resistance in hepatocellular carcinoma by targeting IRAK1.
    Li C, Chen X, Wu J, Heng S, Xu Z, Gu H, Lin E, Wang J, Shan Y.
    Biochem Biophys Res Commun; 2024 Nov 19; 734():150782. PubMed ID: 39378786
    [Abstract] [Full Text] [Related]

  • 13. A Novel lncRNA lncRNA-4045 Promotes the Progression of Hepatocellular Carcinoma by Affecting the Expression of AKR1B10.
    Tan C, Zeng X, Guo X, Mo M, Ma X, Liu B, Liu S, Zeng X, Huang D, Qiu X.
    Dig Dis Sci; 2024 Jul 19; 69(7):2502-2521. PubMed ID: 38662158
    [Abstract] [Full Text] [Related]

  • 14. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM.
    Gastroenterology; 2016 Dec 19; 151(6):1192-1205. PubMed ID: 27614046
    [Abstract] [Full Text] [Related]

  • 15. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
    Torres-Mena JE, Salazar-Villegas KN, Sánchez-Rodríguez R, López-Gabiño B, Del Pozo-Yauner L, Arellanes-Robledo J, Villa-Treviño S, Gutiérrez-Nava MA, Pérez-Carreón JI.
    Dig Dis Sci; 2018 Apr 19; 63(4):934-944. PubMed ID: 29383608
    [Abstract] [Full Text] [Related]

  • 16. HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness.
    Bi L, Ren Y, Feng M, Meng P, Wang Q, Chen W, Jiao Q, Wang Y, Du L, Zhou F, Jiang Y, Chen F, Wang C, Tang B, Wang Y.
    Cancer Res; 2021 Apr 15; 81(8):2015-2028. PubMed ID: 33602787
    [Abstract] [Full Text] [Related]

  • 17. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
    Cao L, Fan X, Jing W, Liang Y, Chen R, Liu Y, Zhu M, Jia R, Wang H, Zhang X, Zhang Y, Zhou X, Zhao J, Guo Y.
    Oncotarget; 2015 Mar 30; 6(9):6627-40. PubMed ID: 25749383
    [Abstract] [Full Text] [Related]

  • 18. Maintenance of stemness by miR-589-5p in hepatocellular carcinoma cells promotes chemoresistance via STAT3 signaling.
    Long J, Jiang C, Liu B, Dai Q, Hua R, Chen C, Zhang B, Li H.
    Cancer Lett; 2018 Jun 01; 423():113-126. PubMed ID: 29196128
    [Abstract] [Full Text] [Related]

  • 19. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
    Sato S, Genda T, Ichida T, Murata A, Tsuzura H, Narita Y, Kanemitsu Y, Ishikawa S, Kikuchi T, Mori M, Hirano K, Iijima K, Wada R, Nagahara A, Watanabe S.
    J Gastroenterol Hepatol; 2016 Jul 01; 31(7):1315-22. PubMed ID: 26758591
    [Abstract] [Full Text] [Related]

  • 20. CXCL11 promotes self-renewal and tumorigenicity of α2δ1+ liver tumor-initiating cells through CXCR3/ERK1/2 signaling.
    Zhang Y, Zhao W, Li S, Lv M, Yang X, Li M, Zhang Z.
    Cancer Lett; 2019 May 01; 449():163-171. PubMed ID: 30771435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.